Ardelyx Raises $30M Series B
Ardelyx Inc. has raised $30 million in fresh capital from New Enterprise Associates, CMEA Capital and new investor Amgen Ventures. The Series B round will help advance Ardelyx's pharmaceutical pipeline that includes product candidates to help treat irritable bowel syndrome, chronic kidney disease and type 2 diabetes. The company has raised a total of $56 million since it was formed in 2007. Ardelyx is based in Fremont, Calif.
31 August 2011•5 mins read
